Detalles de la búsqueda
1.
Treatment-related adverse events, including fatal toxicities, in patients with solid tumours receiving neoadjuvant and adjuvant immune checkpoint blockade: a systematic review and meta-analysis of randomised controlled trials.
Lancet Oncol;
25(1): 62-75, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38012893
2.
Exploring the Landscape of Immune Checkpoint Inhibitor-Induced Adverse Events Through Big Data Mining of Pan-Cancer Clinical Trials.
Oncologist;
29(5): 415-421, 2024 May 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38330451
3.
Molecular Characterization of TFE3-Rearranged Renal Cell Carcinoma: A Comparative Study With Papillary and Clear Cell Renal Cell Carcinomas.
Mod Pathol;
37(2): 100404, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38104891
4.
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study.
Hepatology;
76(4): 1000-1012, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35313048
5.
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study.
Liver Int;
43(3): 695-707, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36577703
6.
Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial.
Cancer;
128(16): 3067-3079, 2022 08 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35727053
7.
Immune Checkpoint Inhibitors: The Unexplored Landscape of Geriatric Oncology.
Oncologist;
27(9): 778-789, 2022 09 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35781739
8.
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma.
Liver Int;
42(11): 2538-2547, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35986902
9.
Biological Rationale for Peripheral Blood Cell-Derived Inflammatory Indices and Related Prognostic Scores in Patients with Advanced Non-Small-Cell Lung Cancer.
Curr Oncol Rep;
24(12): 1851-1862, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36255605
10.
Outcomes of Pregnancy During Immunotherapy Treatment for Cancer: Analysis of Clinical Trials Sponsored by the National Cancer Institute.
Oncologist;
26(10): e1883-e1886, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34397143
11.
Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort.
Cancer Immunol Immunother;
69(7): 1189, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32347358
12.
Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort.
Cancer Immunol Immunother;
69(7): 1177-1187, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32140762
13.
Accurately addressing double-arm-zero-events studies in meta-analyses - Authors' reply.
Lancet Oncol;
25(3): e93, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38423061
14.
Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer.
Int J Mol Sci;
19(11)2018 Nov 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30405053
15.
Histiocytic sarcoma as a secondary malignancy: pathobiology, diagnosis, and treatment.
Eur J Haematol;
97(1): 9-16, 2016 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-26990812
16.
Peripheral blood interleukin 6, interleukin 10, and T lymphocyte levels are associated with checkpoint inhibitor induced pneumonitis: a case report.
Acta Oncol;
60(6): 813-817, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33939588
17.
Increasing diversity in clinical trials: Demographic trends at the national cancer institute, 2005-2020.
J Natl Cancer Inst;
2024 Feb 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-38374401
18.
Benchmarking mismatch repair testing for patients with cancer receiving immunotherapy.
Cancer Cell;
42(1): 6-7, 2024 01 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38157866
19.
Association of Baseline Tumor-Specific Neoantigens and CD8+ T-Cell Infiltration With Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors.
JCO Precis Oncol;
8: e2300439, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38330262
20.
Influence of TP53 Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in STK11-Mutant Non-Small-Cell Lung Cancer.
JCO Precis Oncol;
8: e2300371, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38330261